198 related articles for article (PubMed ID: 16025321)
61. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations.
Kehne JH; McCloskey TC; Baron BM; Chi EM; Harrison BL; Whitten JP; Palfreyman MG
Eur J Pharmacol; 1991 Feb; 193(3):283-92. PubMed ID: 1675993
[TBL] [Abstract][Full Text] [Related]
62. Orphanin FQ/nociceptin blocks cocaine-induced behavioral sensitization in rats.
Lutfy K; Khaliq I; Carroll FI; Maidment NT
Psychopharmacology (Berl); 2002 Nov; 164(2):168-76. PubMed ID: 12404079
[TBL] [Abstract][Full Text] [Related]
63. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
64. In vitro agonist effects of nociceptin and [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin(1-13)NH(2) in the mouse and rat colon and the mouse vas deferens.
Menzies JR; Glen T; Davies MR; Paterson SJ; Corbett AD
Eur J Pharmacol; 1999 Dec; 385(2-3):217-23. PubMed ID: 10607879
[TBL] [Abstract][Full Text] [Related]
65. Characterisation and comparison of novel ligands for the nociceptin/orphanin FQ receptor.
Hashiba E; Harrison C; Galo' G; Guerrini R; Rowbotham DJ; Smith G; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):28-33. PubMed ID: 11191833
[TBL] [Abstract][Full Text] [Related]
66. The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity.
Shoblock JR
CNS Drug Rev; 2007; 13(1):107-36. PubMed ID: 17461893
[TBL] [Abstract][Full Text] [Related]
67. The selective sigma2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents.
Sánchez C; Arnt J; Costall B; Kelly ME; Meier E; Naylor RJ; Perregaard J
J Pharmacol Exp Ther; 1997 Dec; 283(3):1323-32. PubMed ID: 9400007
[TBL] [Abstract][Full Text] [Related]
68. Reversal of stress- and CRF-induced anorexia in rats by the synthetic nociceptin/orphanin FQ receptor agonist, Ro 64-6198.
Ciccocioppo R; Biondini M; Antonelli L; Wichmann J; Jenck F; Massi M
Psychopharmacology (Berl); 2002 May; 161(2):113-9. PubMed ID: 11981590
[TBL] [Abstract][Full Text] [Related]
69. Participation of the nociceptin/orphanin FQ receptor in ethanol-mediated locomotor activation and ethanol intake in preweanling rats.
Miranda-Morales RS; Nizhnikov ME; Waters DH; Spear NE
Behav Brain Res; 2013 May; 245():137-44. PubMed ID: 23439216
[TBL] [Abstract][Full Text] [Related]
70. A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models.
Rorick-Kehn LM; Ciccocioppo R; Wong CJ; Witkin JM; Martinez-Grau MA; Stopponi S; Adams BL; Katner JS; Perry KW; Toledo MA; Diaz N; Lafuente C; Jiménez A; Benito A; Pedregal C; Weiss F; Statnick MA
Alcohol Clin Exp Res; 2016 May; 40(5):945-54. PubMed ID: 27084498
[TBL] [Abstract][Full Text] [Related]
71. Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats.
Sukhtankar DD; Lagorio CH; Ko MC
Eur J Pharmacol; 2014 Dec; 745():182-9. PubMed ID: 25446568
[TBL] [Abstract][Full Text] [Related]
72. Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide.
Mead A; Li M; Kapur S
Pharmacol Biochem Behav; 2008 Oct; 90(4):551-62. PubMed ID: 18547622
[TBL] [Abstract][Full Text] [Related]
73. Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders.
Leonard SK; Dwyer JM; Sukoff Rizzo SJ; Platt B; Logue SF; Neal SJ; Malberg JE; Beyer CE; Schechter LE; Rosenzweig-Lipson S; Ring RH
Psychopharmacology (Berl); 2008 May; 197(4):601-11. PubMed ID: 18311561
[TBL] [Abstract][Full Text] [Related]
74. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
Spagnolo B; Carrà G; Fantin M; Fischetti C; Hebbes C; McDonald J; Barnes TA; Rizzi A; Trapella C; Fanton G; Morari M; Lambert DG; Regoli D; Calò G
J Pharmacol Exp Ther; 2007 Jun; 321(3):961-7. PubMed ID: 17329552
[TBL] [Abstract][Full Text] [Related]
75. Independence of benzodiazepine and opiate action in the suppression of isolation distress in rat pups.
Carden SE; Hofer MA
Behav Neurosci; 1990 Feb; 104(1):160-6. PubMed ID: 2107826
[TBL] [Abstract][Full Text] [Related]
76. Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups.
Kehne JH; Coverdale S; McCloskey TC; Hoffman DC; Cassella JV
Neuropharmacology; 2000 Jun; 39(8):1357-67. PubMed ID: 10818252
[TBL] [Abstract][Full Text] [Related]
77. Non-peptidergic OP4 receptor agonist inhibits morphine antinociception but does not influence morphine dependence.
Kotlinska J; Wichmann J; Rafalski P; Talarek S; Dylag T; Silberring J
Neuroreport; 2003 Mar; 14(4):601-4. PubMed ID: 12657894
[TBL] [Abstract][Full Text] [Related]
78. Anxiolytic-like actions of the selective 5-HT4 receptor antagonists SB 204070A and SB 207266A in rats.
Kennett GA; Bright F; Trail B; Blackburn TP; Sanger GJ
Neuropharmacology; 1997; 36(4-5):707-12. PubMed ID: 9225297
[TBL] [Abstract][Full Text] [Related]
79. Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test.
Rizzi A; Ruzza C; Bianco S; Trapella C; Calo' G
Peptides; 2017 Aug; 94():71-77. PubMed ID: 28697954
[TBL] [Abstract][Full Text] [Related]
80. The effects of opioid and benzodiazepine antagonists on dam-induced reductions in rat pup isolation distress.
Carden SE; Hofer MA
Dev Psychobiol; 1990 Dec; 23(8):797-808. PubMed ID: 1964442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
